Finlandia - finés - Fimea (Suomen lääkevirasto)

bayer oy - norethisterone - tabletti - 5 mg - noretisteroni

Finlandia - finés - Fimea (Suomen lääkevirasto)

bayer oy - levonorgestrelum,ethinylestradiolum - tabletti, päällystetty - levonorgestreeli ja etinyyliestradioli

Finlandia - finés - Fimea (Suomen lääkevirasto)

bayer oy - ethinylestradiolum,levonorgestrelum - tabletti, päällystetty - levonorgestreeli ja etinyyliestradioli

Finlandia - finés - Fimea (Suomen lääkevirasto)

actavis group ptc ehf - ethinylestradiolum,drospirenonum - tabletti, kalvopäällysteinen - 0.02 mg / 3 mg - drospirenoni ja etinyyliestradioli

Finlandia - finés - Fimea (Suomen lääkevirasto)

bayer oy - gestodenum,ethinylestradiolum - tabletti, päällystetty - gestodeeni ja etinyyliestradioli

Unión Europea - finés - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - atsakitidiini - leukemia, myeloidi, akuutti - antineoplastiset aineet - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Finlandia - finés - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - docetaxelum - infuusiokonsentraatti, liuosta varten - 20 mg/ml - dosetakseli

Unión Europea - finés - EMA (European Medicines Agency)

pfizer europe ma eeig - inotuzumab ozogamicin - prekursorisolujen lymfoblastinen leukemia-lymfooma - antineoplastiset aineet - besponsa on merkitty monoterapiana aikuisten hoidossa, joilla on uusiutunut tai tulenkestoinen cd22-positiivinen b-solu-esiaste akuutti lymfaattinen leukemia (all). aikuispotilailla, joilla on philadelphia-kromosomin positiivinen (ph +) uusiutunut tai tulenkestävä b-soluprekursori all, pitäisi olla epäonnistunut hoito vähintään 1 tyrosiinikinaasi-inhibiittorilla (tki).

Unión Europea - finés - EMA (European Medicines Agency)

sandoz gmbh - rituksimabi - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastiset aineet - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. on vain vähän tietoa turvallisuudesta ja tehosta potilailla, joita on aiemmin hoidettu monoklonaalisia vasta-aineita, mukaan lukien rituksimabi tai potilaat eivät sietäneet aiemman rituksimabi plus kemoterapiaa. ks. kohta 5. 1 lisätietoja. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituksimabi on todettu hidastavan etenemistä nivelvaurioita mitattuna x-ray ja parantaa fyysistä toimintakykyä, kun sitä annetaan yhdessä metotreksaatin kanssa. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

Finlandia - finés - Fimea (Suomen lääkevirasto)

bayer oy - drospirenonum,ethinylestradiolum betadex-clathratum - tabletti, kalvopäällysteinen - 0.02 mg / 3 mg - drospirenoni ja etinyyliestradioli